IP Library Granted Patent US 7,371,842
Granted Patent B2
US 7,371,842 · App. 10/511,270 · Granted May 13, 2008

Polynucleotide encoding a 35 KDA protein thats binds to WF00144

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,371,842
App. No.
10/511,270
Granted
May 13, 2008
Kind
B2
Abstract

It is intended to provide a protein participating in the regulation of sugar production, a polynucleotide encoding the same, a method of screening a compound participating in the regulation of sugar production and a drug for treating or preventing diabetes which contains the compound participating in the regulation of sugar production. A polynucleotide encoding a protein specifically binding to a substance WF00144 is found out from rat liver cells and thus a protein participating in the regulation of sugar production and a polynucleotide encoding the same are provided. Moreover, a method and a substance relating to a method of treating and preventing diabetes are found out and thus a method of treating diabetes relating to the regulation of sugar production relating to the method of treating and preventing diabetes is provided.

Claims (16)

1. An isolated polynucleotide:

which consists of a coding region for a polypeptide, wherein said polypeptide binds to WF00144 and has a molecular weight of about 35 kD; and

said polynucleotide has at least 96% sequence identity to SEQ ID NO: 1, or which hybridizes to the complement of SEQ ID NO: 1 under stringent conditions, wherein stringent conditions comprise washing in 0.1×SSC and 0.1% SDS at 68° C.

2. The isolated polynucleotide of claim 1 , which has at least 96% sequence identity to SEQ ID NO: 1.

3. The isolated polynucleotide of claim 1 , which hybridizes to the complement of SEQ ID NO: 1 under stringent conditions, wherein stringent conditions comprising washing in 0.1×SSC and 0.1% SDS at 68° C.

4. The isolated polynucleotide of claim 1 , which encodes a polypeptide comprising SEQ ID NO: 2.

5. The isolated polynucleotide of claim 1 , which consists of SEQ ID NO: 1.

6. The isolated polynucleotide of claim 1 , wherein said encoded polypeptide has at least 96% sequence identity to SEQ ID NO: 2.

7. The isolated polynucleotide of claim 1 , which encodes a polypeptide in which one to five of the amino acid residues in SEQ ID NO: 2 are different than the corresponding amino acids in SEQ ID NO: 2.

8. An expression vector comprising the polynucleotide of claim 1 , which expresses a polypeptide that binds to WF00144 and has a molecular weight of about 35 kDa.

9. A transformant comprising the polynucleotide of claim 1 .

10. The full complement of the polynucleotide of claim 1 .

11. The isolated polynucleotide of claim 1 , further consisting of at its 5′ end an oligonucleotide encoding histidine, lysine or arginine.

12. A viral vector comprising the isolated polynucleotide of claim 1 .

13. A liposome comprising the isolated polynucleotide of claim 1 .

14. A method for making a polypeptide that binds to WF00144, comprising culturing the transformant of claim 9 under conditions suitable for production of a polypeptide that binds to WF00144, and recovering said polypeptide.

Assignments (3)
MERGER Recorded Dec 12, 2005
From: FUJISAWA PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 017073/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2005
From: NAKAJIMA, HIDENORI; OHKUBO, MITSURU; YOSHIMURA, SEIJI; NISHIO, NOBUYA; NISHIO, KAORI
To: FUJISAWA PHARMACEUTICAL CO., LTD.
Reel/Frame 016751/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2005
From: NAKAJIMA, HIDENORI; OHKUBO, MITSURU; YOSHIMURA, SEIJI; NISHIO, NOBUYA; NISHIO, KAORI
To: ASTELLAS PHARMA INC.
Reel/Frame 016589/0496 →